Halozyme reports Q3 non-GAAP EPS $1.72, consensus $1.61

Reports Q3 revenue $354.3M, consensus $339.1M. “Halozyme (HALO) delivered another record quarter, with royalty revenue increasing 52% year-over-year to $236M. This strong performance drove total revenue to a record $354M, representing a 22% increase year-over-year….We project achievement of the two remaining catalysts in Q4. Building on the progress to date, we project the revenue growth contribution of our four additional launched ENHANZE product, Ocrevus Zunuvo, Tecentriq Hybreza, Opdivo Qvantig and Rybrevant SC to increase in 2026 and beyond,” commented CEO Helen Torley. “Based on our continued strong performance of our core ENHANZE technology, we are pleased to raise our guidance ranges, with royalty revenue growth of approximately 50% for the full year. As we look ahead, our planned acquisition of Elektrofi represents a significant opportunity to amplify our opportunity in subcutaneous drug delivery by introducing a complementary high-concentration technology that has three large biopharma partner agreements in place. With royalty contributions from Elektrofi’s Hypercon projected to begin in 2030, we are building a multi-platform engine for long-term growth, positioning Halozyme to deliver sustained value for patients, partners, and our shareholders.”